What is the address of Dr. Van der Heyden Jan?

The registered office of Dr. Van der Heyden Jan is located at Asterstraat 17, 8300 Knokke-Heist.

Is Dr. Van der Heyden Jan still active?

Yes. According to the CBE (19 September 2026) Dr. Van der Heyden Jan is active, legal situation “Normale toestand”, started on 12 April 2019.

Is Dr. Van der Heyden Jan registered on Peppol?

Yes, Dr. Van der Heyden Jan is registered on the Peppol network with ID 0208:0724839428.

What is the enterprise number of Dr. Van der Heyden Jan?

The enterprise number of Dr. Van der Heyden Jan is BE0724839428.

When was Dr. Van der Heyden Jan founded?

Dr. Van der Heyden Jan was founded on 12 April 2019.

Who are the directors of Dr. Van der Heyden Jan?

According to the 2025 annual accounts, the directors of Dr. Van der Heyden Jan are: Jan Van der Heyden, Vanessa Schelfhout.

Is Dr. Van der Heyden Jan a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 12 April 2019; 4 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did Dr. Van der Heyden Jan make in 2025?

Dr. Van der Heyden Jan posted a profit after taxes of € 680,239 in financial year 2025.

What is the revenue of Dr. Van der Heyden Jan?

As a small company, Dr. Van der Heyden Jan is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 939,781.

How many employees does Dr. Van der Heyden Jan have?

According to the 2025 annual accounts, Dr. Van der Heyden Jan has 0 full-time equivalents (FTE).

Dr. Van der Heyden Jan (Private Limited) - Knokke-Heist

Dossier Dr. Van der Heyden Jan, printed on 19 September 2026 from databakkes.be/en/0724839428/dr-van-der-heyden-jan. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Dr. Van der Heyden Jan from Knokke-Heist, company number BE0724839428, closed financial year 2025 with a result of € 680,239 after tax. For that financial year Dr. Van der Heyden Jan recorded a gross margin of € 939,781 and equity of € 18,550. Compared with financial year 2024, the result moved from € 558,077 to € 680,239. Profitable, and profit is growing. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on March 30, 2026.

What it is worth Healthy

€ 18,550

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 680,239

▲ 22% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 359,025

▲ 44% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 680,239 paid out

100 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Vehicles and equipment

€ 48,049

▼ 40% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 48,376

▼ 41% vs 2024

€ 32,025 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 7,824

▲ 130% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 3,075

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 858,174 Gross margin 2022: € 858,174 First fiscal year in the series	€ 818,932 Gross margin 2023: € 818,932 ▼ 5% vs 2022 (€ 858,174) Unfavourable step	€ 797,451 Gross margin 2024: € 797,451 ▼ 3% vs 2023 (€ 818,932) Unfavourable step	€ 939,781 Gross margin 2025: € 939,781 ▲ 18% vs 2024 (€ 797,451) Favourable step	▲ 18%
Profit after taxes	€ 627,377 Profit after taxes 2022: € 627,377 First fiscal year in the series	€ 584,236 Profit after taxes 2023: € 584,236 ▼ 7% vs 2022 (€ 627,377) Unfavourable step	€ 558,077 Profit after taxes 2024: € 558,077 ▼ 4% vs 2023 (€ 584,236) Unfavourable step	€ 680,239 Profit after taxes 2025: € 680,239 ▲ 22% vs 2024 (€ 558,077) Favourable step	▲ 22%
Equity	€ 20,400 Equity 2022: € 20,400 First fiscal year in the series	€ 18,550 Equity 2023: € 18,550 ▼ 9% vs 2022 (€ 20,400) Unfavourable step	€ 18,550 Equity 2024: € 18,550 Unchanged (€ 18,550) Unchanged	€ 18,550 Equity 2025: € 18,550 Unchanged (€ 18,550) Unchanged
Total debts	€ 952,452 Total debts 2022: € 952,452 First fiscal year in the series	€ 705,266 Total debts 2023: € 705,266 ▼ 26% vs 2022 (€ 952,452) Favourable step	€ 644,093 Total debts 2024: € 644,093 ▼ 9% vs 2023 (€ 705,266) Favourable step	€ 739,514 Total debts 2025: € 739,514 ▲ 15% vs 2024 (€ 644,093) Unfavourable step	▲ 15%
Cash	€ 468,494 Cash 2022: € 468,494 First fiscal year in the series	€ 132,225 Cash 2023: € 132,225 ▼ 72% vs 2022 (€ 468,494) Unfavourable step	€ 249,385 Cash 2024: € 249,385 ▲ 89% vs 2023 (€ 132,225) Favourable step	€ 359,025 Cash 2025: € 359,025 ▲ 44% vs 2024 (€ 249,385) Favourable step	▲ 44%
Retained profit	€ 1,850 Retained profit 2022: € 1,850 First fiscal year in the series	€ 0 Retained profit 2023: € 0 ▼ 100% vs 2022 (€ 1,850) Unfavourable step	€ 0 Retained profit 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Retained profit 2025: € 0 Unchanged (€ 0) Unchanged
Dividend	€ 1,558,503 Dividend 2022: € 1,558,503 First fiscal year in the series	€ 586,086 Dividend 2023: € 586,086 ▼ 62% vs 2022 (€ 1,558,503) Unchanged	€ 558,077 Dividend 2024: € 558,077 ▼ 5% vs 2023 (€ 586,086) Unchanged	€ 680,239 Dividend 2025: € 680,239 ▲ 22% vs 2024 (€ 558,077) Unchanged	▲ 22%
Bank debt	€ 139,716 Bank debt 2022: € 139,716 First fiscal year in the series	€ 109,802 Bank debt 2023: € 109,802 ▼ 21% vs 2022 (€ 139,716) Favourable step	€ 82,612 Bank debt 2024: € 82,612 ▼ 25% vs 2023 (€ 109,802) Favourable step	€ 48,376 Bank debt 2025: € 48,376 ▼ 41% vs 2024 (€ 82,612) Favourable step	▼ 41%
Balance sheet total	€ 972,852 Balance sheet total 2022: € 972,852 First fiscal year in the series	€ 723,816 Balance sheet total 2023: € 723,816 ▼ 26% vs 2022 (€ 972,852) Unchanged	€ 662,643 Balance sheet total 2024: € 662,643 ▼ 8% vs 2023 (€ 723,816) Unchanged	€ 758,064 Balance sheet total 2025: € 758,064 ▲ 14% vs 2024 (€ 662,643) Unchanged	▲ 14%

Key figures of Dr. Van der Heyden Jan, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr. Van der Heyden Jan?

What happened at Dr. Van der Heyden Jan in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Mar 30, 2026 New annual accounts for financial year 2025: profit of € 680,239 (▲ 22% vs 2024). Source: NBB ↗
Apr 12, 2019 New establishment in Knokke-Heist. KBO
Apr 12, 2019 Start of the company according to the CBE. KBO
2019 Jan Van der Heyden became a director. NBB
2019 Vanessa Schelfhout became a director. NBB

In short

From € 627,377 profit in 2022 to € 680,239 profit in 2025.

Paid € 800,377 in corporate taxes since 2022.

Best year ever: 2025, with € 680,239 profit.

Paid out € 3.4 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Dr. Van der Heyden Jan? We notify you, reason included.

Follow Dr. Van der Heyden Jan

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Jan Van der Heyden Vanessa Schelfhout

CATHLAB

Rayos Medicinal

Dr. Van der Heyden Jan

Behind Dr. Van der Heyden Jan are Jan Van der Heyden and Vanessa Schelfhout. The same people are also behind Rayos Medicinal. Jan Van der Heyden is also behind CATHLAB.

See the full network in the app

Directors

According to the 2025 annual accounts

Jan Van der Heyden

Director

Also active at: CATHLAB, Rayos Medicinal

since 2019

Vanessa Schelfhout

Director

Also active at: Rayos Medicinal

since 2019

Establishments

Establishment units

Physical locations of this company

Registered office

Asterstraat 17

8300 Knokke-Heist

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Rayos Medicinal same network

€ 399,185 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0724.839.428
VAT number: BE 0724.839.428
Registered office: Asterstraat 17, 8300 Knokke-Heist
Names & denominations: Dr. Van der Heyden Jan
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 12 April 2019
Peppol: Active · Active since 20 Mar 2025

View on CBE Public ↗ Annual accounts (NBB) ↗